Difficulty: Medium
Average Score: 66%
Practice
Anthracycline (doxorubicin) on rare occasion causes acute inflammatory myocardial injury, but more classically results in dilated cardiomyopathy (DCM) in up to 30% of patients with a cumulative dose of doxorubicin exceeding
Correct answer
D
Rationale
In pharmacology, understanding the cardiotoxic effects of anthracyclines like doxorubicin is crucial for healthcare professionals, especially in pediatric patients. The correct answer is D) 550 mg/m┬▓. This is because doxorubicin-induced dilated cardiomyopathy (DCM) typically occurs in patients who have received cumulative doses exceeding 550 mg/m┬▓.
Option A) 250 mg/m┬▓ is too low of a dose to typically result in doxorubicin-induced DCM. Option B) 350 mg/m┬▓ is also below the threshold dose for developing DCM. Option C) 450 mg/m┬▓, while closer, still falls short of the dose commonly associated with doxorubicin-induced DCM.
Educationally, this question highlights the importance of monitoring cumulative anthracycline doses in pediatric patients to prevent cardiotoxicity. Understanding dose thresholds for adverse effects helps healthcare providers make informed decisions regarding treatment regimens and potential cardiac complications. It reinforces the need for vigilant monitoring and dose adjustments to minimize the risk of cardiomyopathy in pediatric patients receiving anthracycline therapy.
Option A) 250 mg/m┬▓ is too low of a dose to typically result in doxorubicin-induced DCM. Option B) 350 mg/m┬▓ is also below the threshold dose for developing DCM. Option C) 450 mg/m┬▓, while closer, still falls short of the dose commonly associated with doxorubicin-induced DCM.
Educationally, this question highlights the importance of monitoring cumulative anthracycline doses in pediatric patients to prevent cardiotoxicity. Understanding dose thresholds for adverse effects helps healthcare providers make informed decisions regarding treatment regimens and potential cardiac complications. It reinforces the need for vigilant monitoring and dose adjustments to minimize the risk of cardiomyopathy in pediatric patients receiving anthracycline therapy.